Rationale and design of the treatment of hyponatremia based on Lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study

Clinical and Translational Science

Volumn 3, Issue 5, 2010, Pages 249-253

  Abraham, William T ^a   Aranda, Juan M ^b   Boehmer, John P ^c   Elkayam, Uri ^d   Gilbert, Edward M ^e   Gottlieb, Stephen S ^f   Hasenfub, Gerd ^g   Kukin, Marrick ^h   Lowes, Brian D ⁱ   O'Connell, John B ^j   Tavazzi, Luigi ^k   Feldman, Arthur M ^l   Ticho, Barry ^m   Orlandi, Cesare ⁿ  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d LAC USC MEDICAL CENTER   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k GVM Hospitals of Care and Research   (Italy)

^l THOMAS JEFFERSON UNIVERSITY   (United States)

^m BIOGEN   (United States)

ⁿ Cardiokine Inc   (United States)

more..

Author keywords

Arginine vasopressin; Heart failure; Hyponatremia

Indexed keywords

LIXIVAPTAN; PLACEBO;

ARTICLE; BODY WEIGHT; CLINICAL EVALUATION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; HEART FAILURE; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

BENZAMIDES; ENDPOINT DETERMINATION; HUMANS; HYPONATREMIA; PYRROLES;

EID: 78049258954     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2010.00217.x     Document Type: Article

References (30)

1. Schrier RW, Gurevich A, Abraham W. Renal sodium excretion, edematous disorders, and diuretic use. In: Schrier RW, ed. Renaland Electrolyte Disorders. 6th edition. Philadelphia, PA Lippincott Williams and Wilkins; 2002: 64-114.
2. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC. OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007; 28: 980-988.
3. Kearney MT, Fox KA, Lee AJ, Brooksby WP, Shah AM, Flapan A. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002; 40: 1801-1808.
4. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure. JAMA. 2003; 290: 2581-2517.
5. Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clin J Med. 2006; 73(Suppl 2): S4-S12.
6. Yamane Y, Plasma ADH. level in patients with chronic congestive heart failure. Japan Circ J. 1968; 32: 745-759.
7. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981; 305: 263-266.
8. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983; 1: 1385-1390.
9. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005; 46: 1785-1791.
10. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure: implications for fluid and electrolyte disturbances. N Engl J Med. 1999; 341: 577-585.
11. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007; 120(Suppl 1): S1-S21.
12. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol. 1999; 10: 647-663.
13. Funayama H, Nakamura T, Saito T, Yoshimura A, Saito M, Kawakami M, Ishikawa SE. Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int. 2004; 66: 1387-1392.
14. Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med. 2006; 73(Suppl 3): S24-S33.
15. 2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006; 97(7): 1064-1067.
16. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355: 2099-2112.
17. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Orlandi C. Vasopressin receptor blockade in patients with congestive heart failure: results from a randomized, double blind study. Circulation. 2003; 107: 2690-2696.
18. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297: 1319-1331.
19. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297: 1332-1343.
20. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, Albright JD, Ru X, Mazandarani H, Tanikella T, Shepherd C, Ochalski L, Bailey T, Lock TY, Ning X, Taylor JR, Spinelli W. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol. 1998; 449: 439-443.
21. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006; 47: 1615-1621.
22. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001; 104: 2417-2423.
23. Russell SD, Adams K, Shaw JP. Results of a twelve week double-blind, placebo-controlled multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure [abstract]. J Cardiac Failure. 2003; 9(Suppl 1): S60.
24. Dhar S, Koul D, D'Alonzo GE. Current concepts in diastolic heart failure. J Am Osteopath Assoc. 2008; 108: 203-209.
25. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP, for the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149: 209-216.
26. Fals-Stewart W. An interrater reliability study of the trail making test (parts A and B). Percept Mot Skills. 1992; 74: 39-42.
27. Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci. 2006; 18: 54-63.
28. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008; 7: 779-786.
29. Hlatky MA, Bacon C, Boothroyd D, Mahanna E, Reves JG, Newman MF, Johnstone I, Winston C, Brooks MM, Rosen AD, Mark DB, Pitt B, Rogers W, Ryan T, Wiens R, Blumenthal JA. Cognitive function 5 years after randomization to coronary angioplasty or coronary artery bypass graft surgery. Circulation. 1997; 96(Suppl 0): II-11-4.
30. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficit. Am J Med. 2006; 119: 71.e1-e8.